

DUPILUMAB IS A MONOCLONAL ANTIBODY USED FOR THE TREATMENT OF A TOPIC DERMATITIS. THIS STUDY EVALUATES THE EFFECTIVENESS AND PERSISTENCE.

DUPILUMAB PRESENTS GOOD EFFECTIVENESS AND PERSISTENCE

Esteve López V., Company Albir MJ., Vicente Escrig E., Riera Calabuig A., García Muñoz S., Belles Medall MD., Ferrando Piqueres R.

Hospital General Universitario de Castellón, Castellón, Spain

Contact: esteve_viclop@gva.es

5PSQ-070



BACKGROUND AND IMPORTANCE

Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease characterised by severe itching and skin lesions caused by defects in the skin barrier and dysregulation of the immune system. Dupilumab is an anti-IL-4/13 monoclonal antibody approved for the treatment of moderate to severe AD.

OBJECTIVE




To evaluate the effectiveness and persistence of Dupilumab in moderate-severe AD.

MATERIALS AND METHODS

Observational and retrospective study of patients on treatment with Dupilumab for moderate-severe AD from March 2020 to September 2023 in a tertiary hospital. Effectiveness was assessed with the EASI (Eczema Area and Severity Index) and IGA (Investigator Global Assessment) scales at weeks 16, 24 and 52. Treatment was considered effective when the EASI had been reduced by 50% (EASI50) and when the IGA had been reduced by <2 points.

RESULTS

- **39 patients (59% male)**
- **Median age 31 years**
- **Dosage: 300 mg every 2 weeks**



Dupilumab (10%)

Tralokinumab (7%)

Upadacitinib (3%)

CONCLUSIONS

Dupilumab treatment shows good persistence and effectiveness in AD, although further studies of longer duration are needed to establish the usefulness of dupilumab in long-term clinical practice conditions.